Clinical trial
A 12-week Efficacy Evaluation of WBI-1001 Cream in Patients With Atopic Dermatitis: A Multi-centered, Double-blinded Study (6-week Placebo-controlled Phase Followed by a 6-week Non-placebo Controlled Phase).
NCT01098734 is registered in ClinicalTrials.gov with Welichem Biotech Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 12-week Efficacy Evaluation of WBI-1001 Cream in Patients With Atopic Dermatitis: A Multi-centered, Double-blinded Study (6-week Placebo-controlled Phase Followed by a 6-week Non-placebo Controlled Phase).
- Lead sponsor
- Welichem Biotech Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2009
- Completion date
- November 30, 2010
- Enrollment
- 148 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.